VUDALIMAB
UNII 4I9I5X3Z6N

Substance Identification & Data

This profile provides standardized clinical and technical data for Vudalimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4I9I5X3Z6N.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2329669-72-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4I9I5X3Z6N

CAS Registry Number

2329669-72-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VUDALIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C150463

National Cancer Institute reference terminology for clinical and research data.

INN ID

11464

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-26

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vudalimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VUDALIMAB

Common Names & Synonyms

ANTI-PD-1/ANTI-CTLA-4 XMAB20717

ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC

IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260->227'),(263->230')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN PROGRAMMED CELL DEATH 1) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 .KAPPA.-CHAIN

PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717

VUDALIMAB [INN]

VUDALIMAB [USAN]

VUDALIMAB [WHO-DD]

XMAB-20717